OBV/PTV/r and DSV — Competitive Intelligence Brief

OBV/PTV/r and DSV (OBV/PTV/r and DSV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination. Area: Infectious Disease / Virology.

marketed Direct-acting antiviral (DAA) combination HCV NS5A, NS3/4A protease, NS5B polymerase Infectious Disease / Virology Small molecule

Target snapshot

OBV/PTV/r and DSV (OBV/PTV/r and DSV) — Hannover Medical School. OBV/PTV/r and DSV is a fixed-dose combination of hepatitis C virus (HCV) NS5A inhibitor, NS3/4A protease inhibitor, and NS5B nucleotide polymerase inhibitor that blocks viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OBV/PTV/r and DSV TARGET	OBV/PTV/r and DSV	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B polymerase
DCV/ASV/BMS-791325	DCV/ASV/BMS-791325	Bristol-Myers Squibb	phase 3	Direct-acting antiviral combination (NS5A inhibitor + NS3 protease inhibitor + NS5B polymerase inhibitor)	HCV NS5A, NS3/4A protease, NS5B polymerase
Daclinza and Sunvepra	Daclinza and Sunvepra	Pusan National University Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Grazoprevir/Elbasvir	Grazoprevir/Elbasvir	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
sofosbuvir/velpatasvir crushed	sofosbuvir/velpatasvir crushed	Radboud University Medical Center	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
Grazaoprevir/Elbasavir/RBV	Grazaoprevir/Elbasavir/RBV	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog	HCV NS3/4A protease; HCV NS5A protein; viral RNA polymerase
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination class)

1. Massachusetts General Hospital · 3 drugs in this class
2. Egyptian Liver Hospital · 3 drugs in this class
3. Hannover Medical School · 2 drugs in this class
4. University of Maryland, Baltimore · 2 drugs in this class
5. Iran Hepatitis Network · 2 drugs in this class
6. Partners in Health · 2 drugs in this class
7. HaEmek Medical Center, Israel · 1 drug in this class
8. Almaza Military Fever Hospital · 1 drug in this class
9. Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 1 drug in this class
10. Federal University of São Paulo · 1 drug in this class